Evidence map›Paper›PMID 25386199›Full record

ArticleHepatitis monthly2014

Analytical assessment of interleukin - 23 and -27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a).

Asghar Ashrafi Hafez, Abbas Ahmadi Vasmehjani, Rasoul Baharlou, Seyed Dawood Mousavi Nasab, Mohammad Hasan Davami, Ahmad Najafi, Negar Joharinia, Hasan Rezanezhad, Nayeb Ali Ahmadi, Masoumeh Imanzad

Open access · hybridAbstract read
In one paragraph

Article in Hepatitis monthly, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Asghar Ashrafi HafezCancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Abbas Ahmadi VasmehjaniDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Rasoul BaharlouDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Seyed Dawood Mousavi NasabDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.
Mohammad Hasan DavamiDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Ahmad NajafiDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Negar JohariniaDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Hasan RezanezhadDepartment of Microbiology and Immunology, Jahrom University of Medical Sciences, Jahrom, IR Iran.
Nayeb Ali AhmadiDepartment of Medical Lab Technology and Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Masoumeh ImanzadDepartment of Social Medicine, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, IR Iran ; Young Researchers Club, Shahr-e-Qods branch, Islamic Azad University, Tehran, IR Iran.
Jahrom University of Medical Sciences · IRJahrom University · IRShahid Beheshti University of Medical Sciences · IRTarbiat Modares University · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immune system plays important roles in determining the outcomes of hepatitis C virus (HCV) infection. Interleukin-23 and -27 (IL-23 and IL-27) are two novel IL-12 cytokine family members known to enhance the T-lymphocyte response, but their precise involvement in HCV infection is not well known.

objectivesWe investigated the serum IL-27 and IL-23 levels in patients with HCV infection and in healthy individuals. PATIENTS AND

methodsIn this case-control study, we assessed IL-23 and IL-27 levels in serum of 37 healthy individuals and 64 patients with chronic HCV using Enzyme-linked immunosorbent assay (ELISA). The relationship of cytokines level with liver enzymes (ALT, AST, and ALP), HCV genotype and viral load were analyzed. The differences of these cytokine levels in the groups of treatment and no treatment was compared. HCV genotypes were classified by HCV-specific primers methods. HCV RNA loads were determined by fluorescence quantitative PCR.

resultsSerum level of IL-23 was higher in HCV infected patients compared to control group (P = 0.005). However, no significant difference was seen in IL-27 serum level between patients compared to the control group (P = 0.65). There was no significant difference in IL-23 and IL-27 level between genotype 1 HCV-infected- and 3a HCV-infected- patients. Positive moderate correlation between IL-23 and IL-27 with viral load was found in type 3a and 1 HCV-infected patient. Positive relative correlation was seen between ALT and IL-23 in 1a HCV-infected patients, which was higher than 3a HCV-infected patients; but there were no significant difference between serums liver enzymes with IL-23 and IL-27 in respect to genotype 3a and 1a HCV-infected patients.

conclusionsThese findings may reflect a vigorous pro-inflammatory reaction orchestrated by the host immune system against chronic HCV. Also, a better understanding of the involvement mechanism considering the correlation between other genotypes with inflammatory cytokines in various stages of disease can be obtained.

Indexed as

CytokinesGenotypesHepacivirusHepatitis CInterleukin–23Interleukin-27

Identifiers

PMID25386199
PMCPMC4221962
OpenAlexW2163209570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.